CJC-1295 (without DAC) and Sermorelin Interaction

Monitor
Mechanism-based 47% confidence

CJC-1295 (without DAC) and Sermorelin have an interaction requiring monitoring for interaction with 47% confidence. Both CJC-1295 (without DAC) and Sermorelin affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). Both compounds affect the gi tract and pituitary, so monitoring these systems is recommended.

Compound Profiles

CJC-1295 (without DAC)

Short-Acting Growth Hormone Releasing Hormone Analog

Binds GHRH receptors on somatotroph cells in the pituitary gland, stimulating cAMP production and physiological GH pulses. The brief 30-minute half-life allows pulsatile release versus prolonged elevation.

Half-life: 30 minutes - 2 hours Typical dose: 100-300mcg per injection growth hormone, weight loss
ghrh receptor carcinogenic riskestrogenicinsulin disruptingteratogenic
View full profile

Sermorelin

GHRH Analog | Growth Hormone Releasing Hormone

Subcutaneous injection provides optimal bioavailability for binding GHRH receptors, stimulating pulsatile GH release while maintaining hypothalamic-pituitary axis integrity and allowing natural somatostatin negative feedback..

Half-life: 10-12 minutes Typical dose: 200-300mcg per dose (up to 500mcg for athletic performance) growth hormone, weight loss
estrogen receptorghrh receptor carcinogenic riskinsulin disruptingteratogenic
View full profile

Combined Organ Load

GI Tract
low
Pituitary
low

Shared Safety Flags

2x 2 compounds share the carcinogenic-risk safety flag (CJC-1295 (without DAC), Sermorelin). Monitor accordingly.
2x 2 compounds affect insulin sensitivity (CJC-1295 (without DAC), Sermorelin). Monitor fasting glucose and HbA1c.
2x 2 compounds share the teratogenic safety flag (CJC-1295 (without DAC), Sermorelin). Monitor accordingly.

Frequently Asked Questions

Can I take CJC-1295 (without DAC) with Sermorelin?

Yes, but with caution. Both CJC-1295 (without DAC) and Sermorelin affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). Regular monitoring is advised.

Is CJC-1295 (without DAC) and Sermorelin safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: carcinogenic risk, insulin disrupting, teratogenic. Monitor accordingly.

What are the interactions between CJC-1295 (without DAC) and Sermorelin?

Both CJC-1295 (without DAC) and Sermorelin affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). This assessment has 47% confidence and is inferred from pharmacological mechanism analysis.

How should I time CJC-1295 (without DAC) and Sermorelin?

CJC-1295 (without DAC) has a half-life of 30 minutes - 2 hours and Sermorelin has a half-life of 10-12 minutes. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: CJC-1295 (without DAC) vs Sermorelin

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.